Utah Medical Products (UTMD) Q4 2024 earnings summary

Executive summary

• 2024 revenues declined 19% year-over-year, net income fell 17%, and EPS dropped 13%, marking a year of contraction for UTMD.

• Stock price decreased 27%, enabling repurchase of over 8% of shares; no debt remains on the balance sheet.

• Gross and operating margins remained strong despite lower sales, aided by cost controls and favorable product mix.

Financial highlights

• 2024 net sales: $40.9M (down 18.6% YoY); 4Q 2024 net sales: $9.2M (down 25.8% YoY).

• 2024 net income: $13.9M (down 16.6% YoY); 4Q 2024 net income: $2.9M (down 32.3% YoY).

• 2024 diluted EPS: $3.96 (down 13.4% YoY); 4Q 2024 diluted EPS: $0.86 (down 27.4% YoY).

• Adjusted EBITDA for 2024: $19.9M (48.5% of sales, down from 53.0% in 2023).

• Cash and investments at year-end: $83.0M, down $9.9M from 2023 after $20M in share repurchases and $4.3M in dividends.

Outlook and guidance

• 2025 revenues expected to decline again by low to mid-single digits; PendoTECH sales projected to fall by ~$2M, while China distributor and OUS Filshie sales are expected to rebound.

• Domestic direct device sales (excluding Filshie) anticipated to grow by a low single-digit percentage in 2025.

• OUS distributor and Filshie device sales projected to recover in 2025, pending regulatory approvals.